GenapSys Names Jason Myers CEO
REDWOOD CITY, Calif.--(BUSINESS WIRE)--GenapSys Inc. (GenapSys), the company behind the world’s first highly accurate, affordable, and accessible gene sequencer, today announced it has named Jason Myers as its Chief Executive Officer, effective February 15, 2021. He will also join the GenapSys Board of Directors. Myers will succeed Dr. Hesaam Esfandyarpour, founder and CEO of GenapSys since 2010, who will remain as Chairman.
As a strong leader in the biotech industry with a demonstrated track record of scaling businesses and bringing innovative technologies to market, Myers will help GenapSys continue to innovate and expand the reach of its industry-leading solutions. Myers currently serves as a member of the management team and a Director at Invitae, where he leads oncology strategy development. He joined Invitae in 2020 upon the acquisition of ArcherDX, a company he founded and led as President and Chief Executive Officer.
Myers is trained as a biochemist with a wealth of experience in genomics and product development. Prior to founding ArcherDX, Myers led cross-functional platform and sequencing application development for Ion TorrentTM, which was acquired by Life Technologies in 2010. In addition, Myers discovered and successfully licensed a novel loss-of-function RNAI screening product to several leading life science tools companies. Myers received his Ph.D. in Molecular Pharmacology from Stanford University School of Medicine and a Bachelor of Science from Colorado State University.
Dr. Esfandyarpour is the inventor of electronic DNA sequencing, a technology he developed during his Ph.D. work at Stanford University. He has dedicated the past decade to the development of this novel and higher-efficiency DNA sequencing technology, which at its core represents the convergence of multiple fields of science, engineering, chemistry, biology, and computing. Instead of the optical-based technologies traditionally used in the industry, the GenapSys system centers around a pure electronic chip, enabling a simple, elegant, accurate, and low-cost solution.
“I’m thrilled to be joining GenapSys at this moment when the importance of innovative healthcare technology has never been clearer. Hesaam and the team have developed a pioneering sequencer that delivers highly accurate results at a fraction of the cost of other solutions. I’m excited to help further scale and commercialize this technology so that we can deliver the power of sequencing to new communities and industries,” said Myers.
“I am pleased to welcome Jason to the GenapSys team and look forward to partnering with him in this next chapter of our growth. With world-class management and best-in-class technology, I’m confident we will continue to capture the huge opportunities ahead and revolutionize healthcare diagnostics, pharmaceutical discovery, personalized medicine, food testing, forensics, agriculture, biology, and more,” said Esfandyarpour.
About GenapSys Inc.
GenapSys is the company behind the world’s first highly accurate direct electronic sequencing technology. Its system leverages a proprietary electrical microfluidic sequencing chip with a scalable number of detectors, allowing for applications ranging from targeted sequencing of specific amplicons to genome-scale sequencing data collection. The proprietary semiconductor chip-based detection modality allows the system to be compact, scalable, and affordable, empowering the democratization of access to Next-Generation Sequencing.
Founded by Dr. Hesaam Esfandyarpour, GenapSys’ novel sequencing method is revolutionizing genomics discovery, biomedical research, healthcare, diagnostics, agriculture, and a variety of other fields. GenapSys is headquartered in Redwood City, CA. For more information, visit GenapSys.com.